Once-monthly Abilify filed in Japan
This article was originally published in Scrip
Executive Summary
Otsuka Pharmaceutical has filed for the approval in Japan of the once-monthly intramuscularly injected formulation of its atypical antipsychotic Abilify (aripiprazole), for the treatment of schizophrenia.